SG11202005146VA - Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof - Google Patents

Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof

Info

Publication number
SG11202005146VA
SG11202005146VA SG11202005146VA SG11202005146VA SG11202005146VA SG 11202005146V A SG11202005146V A SG 11202005146VA SG 11202005146V A SG11202005146V A SG 11202005146VA SG 11202005146V A SG11202005146V A SG 11202005146VA SG 11202005146V A SG11202005146V A SG 11202005146VA
Authority
SG
Singapore
Prior art keywords
methods
antigen binding
binding molecules
bispecific antigen
leptin receptor
Prior art date
Application number
SG11202005146VA
Inventor
Jesper Gromada
Panayiotis Stevis
Judith ALTAREJOS
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202005146VA publication Critical patent/SG11202005146VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202005146VA 2017-12-18 2018-12-17 Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof SG11202005146VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607137P 2017-12-18 2017-12-18
US201862635406P 2018-02-26 2018-02-26
PCT/US2018/066075 WO2019126071A1 (en) 2017-12-18 2018-12-17 Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202005146VA true SG11202005146VA (en) 2020-06-29

Family

ID=65003567

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005146VA SG11202005146VA (en) 2017-12-18 2018-12-17 Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof

Country Status (13)

Country Link
US (2) US11834500B2 (en)
EP (1) EP3728315A1 (en)
JP (1) JP2021509021A (en)
KR (1) KR20200100089A (en)
CN (1) CN111542540A (en)
AU (1) AU2018390811A1 (en)
BR (1) BR112020012011A2 (en)
CA (1) CA3084385A1 (en)
IL (1) IL275243A (en)
MA (1) MA51289A (en)
MX (1) MX2020006508A (en)
SG (1) SG11202005146VA (en)
WO (1) WO2019126071A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI824372B (en) 2015-10-12 2023-12-01 美商再生元醫藥公司 Antigen-binding proteins that activate the leptin receptor
US11834500B2 (en) 2017-12-18 2023-12-05 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
KR20200141461A (en) 2018-04-06 2020-12-18 리제너론 파마슈티칼스 인코포레이티드 Methods of treatment using leptin receptor agonist antibodies
EP3994168A4 (en) * 2019-07-02 2023-04-05 Shanghaitech University Antibody to leptin receptor
WO2022031869A2 (en) * 2020-08-05 2022-02-10 Synthekine, Inc. Gp130 binding molecules and methods of use
KR20230061390A (en) 2020-08-05 2023-05-08 신테카인, 인크. Compositions and methods related to IL27 receptor binding
US12018085B2 (en) 2020-08-05 2024-06-25 Synthekine, Inc. Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
CN112190691B (en) * 2020-09-23 2022-02-18 南方医科大学 Application of LIFR protein as non-alcoholic fatty liver biomarker and therapeutic target
CN113110048B (en) * 2021-04-13 2022-06-17 中国空气动力研究与发展中心设备设计与测试技术研究所 Nonlinear system output feedback adaptive control system and method adopting HOSM observer
WO2024028773A1 (en) * 2022-08-03 2024-02-08 Pfizer Inc. Anti- il27r antibodies and methods of use thereof
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2898040B2 (en) * 1990-01-26 1999-05-31 忠三 岸本 Antibodies to gp130 protein
US6451523B1 (en) 1994-09-14 2002-09-17 Interneuron Pharmaceuticals, Inc. Detection of a leptin receptor variant and methods for regulating obesity
US5856098A (en) 1994-09-14 1999-01-05 Progenitor, Inc. Detection of a leptin receptor variant
US5643748A (en) 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US5912123A (en) 1994-09-14 1999-06-15 Progenitor, Inc. Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology
FR2733250B1 (en) * 1995-04-21 1997-07-04 Diaclone ANTI-GP130 MONOCLONAL ANTIBODIES, AND USES THEREOF
US6977240B1 (en) 1995-11-27 2005-12-20 Millenium Pharmaceuticals, Inc. Methods of using the OB receptor antibodies to treat bodyweight disorders
US6482927B1 (en) 1995-11-27 2002-11-19 Millennium Pharmaceuticals, Inc. Chimeric proteins comprising the extracellular domain of murine Ob receptor
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
IL125073A0 (en) 1996-01-08 1999-01-26 Genentech Inc Wsx receptor and ligands
AU2476301A (en) 1996-01-16 2001-05-24 Rockefeller University, The DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof
AU1833197A (en) 1996-01-18 1997-08-11 Progenitor, Inc. Detection of a leptin receptor variant and methods for regulating obesity
EP1731164A1 (en) 1996-01-23 2006-12-13 Indevus Pharmaceuticals, Inc. Methods for using the obese gene and its gene product to stimulate hematopoietic development
US7067472B1 (en) 1996-06-04 2006-06-27 The Scripps Research Institute Diagnostic and therapeutic methods related to regulating energy mobilization with OB protein and OB antibodies
IT1288388B1 (en) * 1996-11-19 1998-09-22 Angeletti P Ist Richerche Bio USE OF SUBSTANCES THAT ACTIVATE THE CNTF RECEPTOR (NEUROTROPHIC CHILI FACTOR) FOR THE PREPARATION OF DRUGS FOR THERAPY
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
US6696411B1 (en) 1998-04-22 2004-02-24 Cornell Research Foundation, Inc. Canine erythropoietin gene and recombinant protein
US20040253242A1 (en) 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
FR2852397B1 (en) 2003-03-10 2005-04-29 USE OF THE GENES LEPROTL 1 AND OB-RGRP FOR SCREENING ACTIVE COMPOUNDS ON WEIGHT GRIP OR LOSS OR DIABETES OF A HUMAN OR ANIMAL SUBJECT.
DE10353593A1 (en) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptin antagonist and method for the quantitative measurement of leptin
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US8969291B2 (en) 2004-10-08 2015-03-03 Enzo Therapeutics, Inc. Methods for decreasing leptin levels or activity for treating inflammation
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
PE20071101A1 (en) 2005-08-31 2007-12-21 Amgen Inc POLYPEPTIDES AND ANTIBODIES
PL2041177T3 (en) 2006-06-02 2012-09-28 Regeneron Pharma High affinity antibodies to human il-6 receptor
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
GB0715216D0 (en) 2007-08-03 2007-09-12 Asterion Ltd Leptin
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
KR101398363B1 (en) 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor VIII
CN103476433A (en) 2011-02-10 2013-12-25 罗切格利卡特公司 Improved immunotherapy
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
PT2895513T (en) 2012-09-12 2018-10-08 Genzyme Corp Fc containing polypeptides with altered glycosylation and reduced effector function
TWI682941B (en) 2013-02-01 2020-01-21 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
JP6666848B2 (en) 2014-02-18 2020-03-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1 / OBR complex signaling pathway
EP3215539A4 (en) * 2014-11-06 2018-05-23 Children's Research Institute, Children's National Immunotherapeutics for cancer and autoimmune diseases
TWI824372B (en) 2015-10-12 2023-12-01 美商再生元醫藥公司 Antigen-binding proteins that activate the leptin receptor
CN110167965A (en) 2016-11-08 2019-08-23 瑞泽恩制药公司 The antigen-binding proteins of antagonism leptin receptor
US11834500B2 (en) 2017-12-18 2023-12-05 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof

Also Published As

Publication number Publication date
IL275243A (en) 2020-07-30
MA51289A (en) 2021-03-24
AU2018390811A1 (en) 2020-07-02
JP2021509021A (en) 2021-03-18
BR112020012011A2 (en) 2020-11-24
WO2019126071A1 (en) 2019-06-27
KR20200100089A (en) 2020-08-25
US11834500B2 (en) 2023-12-05
MX2020006508A (en) 2020-09-17
US20240158497A1 (en) 2024-05-16
CA3084385A1 (en) 2019-06-27
US20190185562A1 (en) 2019-06-20
CN111542540A (en) 2020-08-14
EP3728315A1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
IL275243A (en) Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof
IL266599A (en) Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
HUS2300011I1 (en) Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof
ZA201901066B (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
HK1255971A1 (en) Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof
IL259082A (en) Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof
HK1247213A1 (en) Pd-l1 antibody, antigen fragment binding thereof and pharmaceutical use thereof
ZA201700528B (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
IL280002A (en) Antibody molecules that bind cd137 and ox40
IL274121A (en) Bispecific antibodies binding alk-1 and bmpr-2
EP3484488C0 (en) Antigen binding molecules and methods of use thereof
SI3269735T1 (en) Anti-sclerostin antibody, antigen binding fragment and medical use thereof
GB201818281D0 (en) Antibody molecules that bind CD137 and OX40
GB201811407D0 (en) Antibody molecules that bind CD137 and OX40